PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
4 hedge funds and large institutions have $8.97K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
14% less capital invested
Capital invested by funds: $10.4K → $8.97K (-$1.41K)
33% less funds holding
Funds holding: 6 → 4 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WPA
Wealth Preservation Advisors
Chattanooga,
Tennessee
|
-$2.68K |
| 2 |
ACM
Academy Capital Management
Waco,
Texas
|
-$1.02K |
PVCT Hedge Fund Activity: Q2 2026 in Review
4 of the 8,331 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q2 2026, worth a combined $8.97K — down 14% from $10.4K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PVCT and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Wealth Preservation Advisors, exiting entirely with an estimated $2.68K sold.
- 4 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q2 2026, down from 6 in Q1 2026.
- Funds reported $8.97K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q2 2026, down 14% quarter-over-quarter.
- 0 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q2 2026 and 2 closed out, a net change of -2 holders.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q2 2026 was Wealth Preservation Advisors, an estimated $2.68K sold.
Based on aggregated 13F filings for Q2 2026.